Cancer clinical trials in the region Île-de-France
684 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lung cancer
#NCT07098338
#2025-524843-11-00
Sous étude 1 et 2
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required PDL1 statuses
PDL1 Negative (< 1%)
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
EGFR
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Radiotherapy
1 recruiting site
AstraZeneca
Phase 2
Lung cancer
#NCT07098338
#2025-524843-11-00
Sous-étude 3
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
AstraZeneca
Phase 2
Sarcoma and GIST
#NCT05182164
#2023-509496-16-00
Sarcome pléomorphe indifférencié avancé
Required histologic types
Soft tissue sarcoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
6 recruiting sites
Institut Bergonié
Phase 2
Sarcoma and GIST
#NCT05182164
#2023-509496-16-00
Ostéosarcome osseux ou extra-squelettique
Required histologic types
Bone sarcoma
Required histologic sub types
Osteosarcoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
6 recruiting sites
Institut Bergonié
Phase 2
Sarcoma and GIST
#NCT05182164
#2023-509496-16-00
Sarcome d’Ewing
Required histologic types
Bone sarcoma
Required histologic sub types
Ewing tumor
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Immunotherapy
6 recruiting sites
Institut Bergonié, Merck Sharp & Dohme LLC
Phase 2
Skin cancer
#NCT06172478
#2023-507641-29-00
Melanoma Cohort
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Daiichi Sankyo
Phase 2
Skin cancer
#NCT06961006
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
3 recruiting sites
Merck Sharp & Dohme LLC
Phase 2
Skin cancer
#NCT07230613
#2025-522127-95-00
Required histologic types
Melanoma
Required histologic sub types
Nodular melanoma
Lentigo maligna melanoma
Superficial spreading melanoma
Acral lentiginous melanoma
Achromic melanoma
Mucosal melanoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
UNICANCER
Phase 2
Head and neck cancer
#NCT06769698
#2024-517620-19-00
Required histologic types
Oral cavity
Oropharynx
Hypopharynx
Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required HPV statuses
HPV Positive
HPV Negative
Required CPS scores
CPS Positive (1 <= X < 20)
CPS Positive (X >= 20)
3 recruiting sites
Regeneron Pharmaceuticals
Phase 2
Skin cancer
#NCT05561634
Required histologic types
Basal cell carcinoma
Required disease stage
Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Radiotherapy
2 recruiting sites
CHU Lille